Concepedia

Publication | Closed Access

Combined Treatment of Bladder Cancer Cell Lines with Lapatinib and Varying Chemotherapy Regimens—Evidence of Schedule-Dependent Synergy

DOI

54

Citations

25

References

2007

Year

Lynsey A. McHugh, Marina Kriajevska, J. Kilian Mellon, T.R. Leyshon Griffiths
Urology

References

YearCitations

Global Cancer Statistics, 2002

Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay,

CA A Cancer Journal for Clinicians

2005

18.4K

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella,

New England Journal of Medicine

2004

11.4K

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Hans von der Maase, Steen Werner Hansen, J.T. Roberts,

Journal of Clinical Oncology

2000

2.3K

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giuseppe Giaccone, Roy S. Herbst, Christian Manegold,

Journal of Clinical Oncology

2004

1.7K

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Roy S. Herbst, Giuseppe Giaccone, Joan H. Schiller,

Journal of Clinical Oncology

2004

1.7K

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald,

Cancer Research

2004

1.1K

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Patrick J. Loehrer, Lawrence H. Einhorn, Paul Elson,

Journal of Clinical Oncology

1992

984

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith,

Oncogene

2002

664

Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium

Cora N. Sternberg, Alan Yagoda, Howard I. Scher,

The Journal of Urology

1985

659

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

C. Logothetis, F. H. Dexeus, Laura Finn,

Journal of Clinical Oncology

1990

616

Page 1